- Home
- GAME vs GDTC Comparison
GAME vs GDTC Comparison
Compare GAME & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- GDTC
- Stock Information
- Founded
- GAME 2011
- GDTC 2018
- Country
- GAME United States
- GDTC Singapore
- Employees
- GAME N/A
- GDTC N/A
- Industry
- GAME
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- GDTC Health Care
- Exchange
- GAME Nasdaq
- GDTC Nasdaq
- Market Cap
- GAME 27.2M
- GDTC 28.0M
- IPO Year
- GAME 2009
- GDTC 2023
- Fundamental
- Price
- GAME $2.07
- GDTC $2.14
- Analyst Decision
- GAME Strong Buy
- GDTC Buy
- Analyst Count
- GAME 3
- GDTC 1
- Target Price
- GAME $3.67
- GDTC $5.00
- AVG Volume (30 Days)
- GAME 1.4M
- GDTC 5.7K
- Earning Date
- GAME 08-13-2025
- GDTC 01-01-0001
- Dividend Yield
- GAME N/A
- GDTC N/A
- EPS Growth
- GAME N/A
- GDTC N/A
- EPS
- GAME N/A
- GDTC N/A
- Revenue
- GAME $99,579,536.00
- GDTC $368,838.00
- Revenue This Year
- GAME $6.08
- GDTC $5.37
- Revenue Next Year
- GAME $21.94
- GDTC N/A
- P/E Ratio
- GAME N/A
- GDTC N/A
- Revenue Growth
- GAME 77.06
- GDTC N/A
- 52 Week Low
- GAME $0.50
- GDTC $1.20
- 52 Week High
- GAME $1.64
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- GAME 92.95
- GDTC 44.67
- Support Level
- GAME $0.73
- GDTC $2.08
- Resistance Level
- GAME $0.97
- GDTC $2.31
- Average True Range (ATR)
- GAME 0.18
- GDTC 0.11
- MACD
- GAME 0.16
- GDTC -0.00
- Stochastic Oscillator
- GAME 99.53
- GDTC 12.18
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.